Amadae, S. M. (2003) Rationalizing Capitalist Democracy (Chicago, IL: University of Chicago Press).
2.
Anderson, Gerard & Jean-Pierre Poullier (1999) ‘Health Spending, Access and Outcomes: Trends in Industrialized Countries’, Health Affairs18(3): 178-192.
3.
Angell, Marcia (2004) The Truth about the Drug Companies: How They Deceive Us and What to Do About It (New York: Random House).
4.
Ashmore, Malcolm, Michael Mulkay & Trevor Pinch (1989) Health and Efficiency (Milton Keynes, Bucks.: Open University Press).
5.
Avorn, Jerry (2004) Powerful Medicines: The Benefits, Risks and Costs of Prescription Drugs (New York: Knopf).
6.
Berenson, Alex (2004) ‘Bad Medicine for Pillmakers’, New York Times (18 December): A1-A1.
7.
Berenson, Alex (2005a) ‘Evidence in Vioxx Suits Shows Intervention by Merck Officials’, New York Times (24 April): A1-A1.
8.
Berenson, Alex (2005b) ‘Despite Vow, Drug Makers Still Withhold Data’, New York Times (31 May 31): A1-A1.
9.
Daemmrich, Arthur (2004) Pharmacopolitics: Drug Regulation in the US and Germany (Chapel Hill, NC: University of North Carolina Press).
10.
DiMasi, Joseph, Ronald Hansen & Henry Grabowski (2003) ‘The Price of Innovation: New Estimates of Drug Development Costs’, Journal of Health Economics22: 151-185.
11.
DiMasi, Joseph, Ronald Hansen & Henry Grabowski (2004) ‘Assessing Claims about the Cost of New Drug Development’, available at <www.csdd.tufts.edu/_documents>.
12.
Drahos, Peter & John Braithwaite (2002) Information Feudalism (New York: Free Press).
13.
Eisenberg, Rebecca (2003) ‘Patents, Product Exclusivity, and Information Dissemination: How Law Directs Biopharmaceutical R&D’, Fordham Law Review72: 477-491.
14.
Gladwell, Malcolm. (2004) ‘High Prices’, New Yorker (25 October); available at <www.newyorker.com/printable/?critics/041025crat_atlarge>.
15.
Goodyear, Michael (2006) ‘Learning from the TGN1412 Trial’, British Medical Journal (25 March) 332: 677-678.
16.
Goozner, Merrill (2004) The $800 Million Pill (Berkeley, CA: University of California Press).
17.
Harris, Gardiner (2005) ‘FDA Moves toward More Openness with the Public’, New York Times (20 February).
18.
Healy, David (2002) The Creation of Psychopharmacology (Cambridge, MA: Harvard University Press).
19.
Huber, Peter (2006) ‘Of Pills and Profits’, Conmentary, July/August: 21-28.
20.
Judson, Horace (2004) The Great Betrayal: Fraud in Science (New York: Harcourt).
21.
Kessler, Daniel (2004) ‘Toward Better Drugs for Less’, Science (24 December) 306: 2192-2193.
22.
Marks, Harry (1997) The Progress of Experiment (New York: Cambridge University Press).
23.
Mirowski, Philip (2002) Machine Dreams: Economics becomes a Cyborg Science (New York: Cambridge University Press).
24.
Mirowski, Philip (2004) The Effortless Economy of Science. Durham, NC: Duke University Press.
25.
Mirowski, Philip (2006) ‘Twelve Theses on the History of Demand Theory’, in W. Hands & P. Mirowski (eds), Agreement on Demand (Durham, NC: Duke University Press) (In the Press).
26.
Mirowski, Philip & Esther-Mirjam Sent (2002) Science Bought and Sold (Chicago, IL: University of Chicago Press).
27.
Mirowski, Philip & Esther-Mirjam Sent (2007) ‘The Commercialization of Science and the Response of STS’, in E. Hackett, O Amsterdamska, J. Wajcman & Michael Lynch (eds), Handbook of Science, Technology and Society Studies (Cambridge, MA: MIT Press): 343-379.
28.
Mirowski, Philip & Robert Van Horn (2005) ‘The Contract Research Organization and the Commercialization of Science’, Social Studies of Science35(4): 503-548.
29.
Mowery, David, Richard Nelson, Bhaven Sampat & Arvids Ziedonis (2004) Ivory Tower and Industrial Innovation (Stanford, CA: Stanford Business Books).
30.
Nightingale, Paul & Paul Martin (2004) ‘The Myth of the Biotech Revolution’, Trends in Biotechnology22(11): 564-569.
31.
Porter, Theodore (1995) Trust in Numbers (Princeton, NJ: Princeton University Press).
32.
Rampton, Sheldon & John Stauber (2001) Trust Us, We’re Experts! (New York: Taucher/Putnam).
33.
Rasmussen, Nicolas (2004) ‘Drugs: Bring Back the Good Old Days?’Metascience13: 102-105.
34.
Rasmussen, Nicholas (2005) ‘Drugs and Globalisation’, Metascience14: 73-77.
35.
Reinhardt, Uwe (2004) ‘An Information Infrastructure for the Pharmaceutical Market’, Health Affairs23: 107-112.
36.
Richards, Evelleen (1991) Vitamin C and Cancer: Medicine or Politics? (London: Macmillan).
37.
Sell, Susan (2003) Private Power, Public Law: The Globalization of Intellectual Property Rights (New York: Cambridge University Press).
38.
Sismondo, Sergio (ed.) (2004) Intersections of Pharmaceutical Research and Marketing. Special Issue of Social Studies of Science34(2): 147-292.
39.
Sismondo, Sergio (2005) ‘The Production and Distribution of Pharmaceutical Knowledge’, presentation at ‘Science for Sale’, Cornell University (16 April).
40.
Sismondo, Sergio (2006) ‘Pharmaceutical Company Sponsorship of Research: A Survey’, available at <www.pharmastudies.org>
41.
Slaughter, Sheila & Gary Rhoades (2004) Academic Capitalism and the New Economy (Baltimore, MD: Johns Hopkins University Press).
42.
Walsh, John, Ashish Arora & Wesley Cohen (2003) ‘Effects of Research Tool Patents and Licensing on Biomedical Innovation’, in National Research Council, Patents in the Knowledge-Based Economy (Washington DC: National Academies Press): 285-340
43.
Washburn, Jennifer (2005) University, Inc. (New York: Basic Books).
